Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.278 EUR | -3.03% |
|
-6.44% | -0.78% |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
06-13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.78% | 45.48M | |
+15.85% | 122B | |
+18.91% | 113B | |
+7.25% | 22.84B | |
-18.63% | 20.72B | |
-13.76% | 16.39B | |
-15.96% | 16.51B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma SA Announces Resignation of Richard Pasternak as Director and Chairman